Lucid Diagnostics Inc.

Ticker(s):

LUCD

Country:

Sector & Industry:

,
Business Overview

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Contact & Other Information

Number of Employees:

70

Website:

www.luciddx.com

360 Madison Avenue
25th Floor
New York

,

NY

,

10017
United States
917 813 1828

No content was found.